NFKB1 and melanoma: In another paper, we compared the ONC effectiveness in A375 parental cells with an A375 cells’ subpopulation that had become resistant to dabrafenib, a well-known BRAF-inhibitor targeting BRAF-mutated melanoma [109]: ONC reduced the nuclear NF-κB expression level, the activation of its upstream kinases (IKKs), as well as the activity of its target metalloproteinase-2, irrespectively of the subpopulations tested.